Vaxil Starts Multiple Myeloma Trial
Vaxil Bio Ltd. (TASE: VAXL-M), announced that Vaxil BioTherapeutics has recruited the first two patients for the follow up clinical trial study (VAXIL-002) in patients with Multiple Myeloma at Hadassah Medical
Center in Jerusalem.
The VAXIL-002 trial is a follow-up clinical study to examine the long term safety,
quality of life and long term efficacy of treatment using Vaxil’s therapeutic cancer
vaccine, ImMucin. Enrollment in the VAXIL-002 study is open to those Multiple
Myeloma patients, who participated in Vaxil’s VAXIL-001 trial and who demonstrated
a clinical response i.e. those patients who following treatment with ImMucin in the
VAXIL-001 study did not require any additional treatment for their disease.
Patients enrolled in VAXIL-002 will not receive additional treatment with ImMucin but
will be only monitored. However the trial will provide Vaxil with broader information
regarding the long term effect of ImMucin.
biochem-banner